Evidence map›Paper›PMID 38273993›Full record

ArticleGlobal heart2024

International Atherosclerosis Society Roadmap for Familial Hypercholesterolaemia.

Gerald F Watts, Laney K Jones, Mitchell N Sarkies, Jing Pang, Samuel S Gidding, Peter Libby, Raul D Santos

Open access · goldAbstract read
In one paragraph

Article in Global heart, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 3 countries.

Gerald F WattsSchool of Medicine, University of Western Australia, Perth, Western Australia, Australia.ORCID 0000-0003-2276-1524
Laney K JonesDepartment of Genomic Health, Geisinger, Danville PA, USA.ORCID 0000-0002-6182-5634
Mitchell N SarkiesSchool of Health Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0001-7318-3598
Jing PangSchool of Medicine, University of Western Australia, Perth, Western Australia, Australia.ORCID 0000-0002-9700-6948
Samuel S GiddingDepartment of Genomic Health, Geisinger, Danville PA, USA.ORCID 0000-0002-8557-7225
Peter LibbyDivision of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston MA, USA.ORCID 0000-0002-1502-502X
Raul D SantosLipid Clinic, Heart Institute (InCor), University of São Paulo, São Paulo, Brazil and Hospital Israelita Albert Einstein, São Paulo, Brazil.ORCID 0000-0002-9860-6582
Brigham and Women's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Familial hypercholesterolaemia (FH), a common monogenic disorder, is a preventable cause of premature coronary artery disease and death. Up to 35 million people worldwide have FH, but most remain undetected and undertreated. Several clinical guidelines have addressed the gaps in care of FH, but little focus has been given to implementation science and practice. The International Atherosclerosis Society (IAS) has developed an evidence-informed guidance for the detection and management of patients with FH, supplemented with implementation strategies to optimize contextual models of care. The guidance is partitioned into detection, management and implementation sections. Detection deals with screening, diagnosis, genetic testing and counselling. Management includes risk stratification, treatment of adults and children with heterozygous and homozygous FH, management of FH during pregnancy, and use of lipoprotein apheresis. Specific and general implementation strategies, guided by processes specified by the Expert Recommendations for Implementing Change taxonomy, are provided. Core generic implementation strategies are given for improving care. Nation-specific cholesterol awareness campaigns should be utilized to promote better detection of FH. Integrated models of care should be underpinned by health policy and adapted to meet local, regional and national needs. Clinical centres of excellence are important for taking referrals from the community. General practitioners should work seamlessly with multidisciplinary teams. All health-care providers must receive training in essential skills for caring for patients and families with FH. Management should be supported by shared decision-making and service improvement driven by patient-reported outcomes. Improvements in services require sharing of existing resources that can support care. Advocacy should be utilized to ensure sustainable funding. Digital health technologies and clinical quality registries have special value. Finally, academic-service partnerships need to be developed to identify gaps in care and set priorities for research. This new IAS guidance on FH complements the recent World Heart Federation Cholesterol Roadmap.

Indexed as

AtherosclerosisHyperlipoproteinemia Type IIAdultChildCholesterolCounselingFemaleGenetic TestingHumansPregnancyCholesterolfamilial hypercholesterolaemiaguidanceimplementation practiceimplementation strategiesinternationalroadmap

Identifiers

PMID38273993
PMCPMC10809854
OpenAlexW4391224192

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.